Industry top-down
Diagnostics & Research
Latest reported revenue & EPS across the covered companies in this industry, with year-over-year (YoY) change. From disclosed earnings — not investment advice.
34 companiesMedian revenue YoY: +8.1%EPS beat rate: —
AI industry top-down
진단 및 연구 산업은 중간 매출 성장률 10.4%를 기록하며 전반적인 외형 확장을 이어가고 있습니다. 다만 수익성 측면에서는 다나허와 메드페이스 등이 큰 폭의 EPS 개선을 보인 반면, 아이콘과 라드넷 등은 큰 폭의 EPS 감소를 기록해 기업별 편차가 크게 나타났습니다. 유전체 및 분자진단 기업들의 고성장세와 전통 CRO 기업들의 실적 둔화가 공존하는 흐름입니다.
- 산업 중간 매출 YoY 10.4%로 전반적 외형 성장세 지속
- 유전체 및 진단 기업군 중심의 20~40%대 높은 매출 성장
- 주요 대형 장비 및 랩 기업들의 한 자릿수 안정적 매출 흐름
Where companies diverge: 매출 성장에도 불구하고 기업별 EPS YoY가 -59%에서 +60%까지 극단적 분화 · 찰스리버의 외형 역성장(-2.7%)과 워터스의 세 자릿수 급증 간 실적 양극화
AI synthesis of disclosed results and analyst research across these companies — not investment advice.
Companies — latest quarter
| Company | Period | Revenue | Rev YoY | EPS | EPS YoY | Surprise |
|---|---|---|---|---|---|---|
| TMOTHERMO FISHER SCIENTIFIC INC. | FY2026 Q3 | $12.14B | +9.1% | $4.64 | +8.7% | — |
| DHRDANAHER CORP /DE/ | FY2026 Q3 | $6.55B | +8.3% | $1.75 | +37.8% | — |
| IDXXIDEXX LABORATORIES INC /DE | FY2026 Q3 | $1.21B | +9.9% | $4.01 | +17.9% | — |
| AAGILENT TECHNOLOGIES, INC. | FY2026 Q3 | $1.88B | +8.1% | $1.28 | +8.5% | — |
| WATWATERS CORP /DE/ | FY2026 Q3 | $1.77B | +120.9% | $0.82 | -67.2% | — |
| NTRANatera, Inc. | FY2026 Q3 | $793.98M | +34.1% | $-0.42 | — | — |
| IQVIQVIA HOLDINGS INC. | FY2026 Q3 | $4.43B | +8.0% | $2.10 | +8.8% | — |
| MTDMETTLER TOLEDO INTERNATIONAL INC/ | FY2026 Q3 | $1.09B | +6.3% | $12.29 | +16.3% | — |
| ILMNILLUMINA, INC. | FY2026 Q3 | $1.13B | +4.2% | $1.43 | +45.9% | — |
| LHLABCORP HOLDINGS INC. | FY2026 Q3 | $3.81B | +6.9% | $3.22 | +3.2% | — |
| DGXQUEST DIAGNOSTICS INC | FY2026 Q3 | $3.1B | +10.0% | $2.78 | +28.7% | — |
| GHGuardant Health, Inc. | FY2026 Q3 | $360.98M | +36.1% | $-0.93 | — | — |
| MEDPMedpace Holdings, Inc. | FY2026 Q3 | $716M | +8.5% | $4.84 | +25.4% | — |
| RVTYREVVITY, INC. | FY2026 Q3 | $728.9M | +4.3% | $0.56 | +40.0% | — |
| CRLCHARLES RIVER LABORATORIES INTERNATIONAL, INC. | FY2026 Q3 | $982.73M | -2.2% | $6.86 | — | — |
| ICLRICON PLC | FY2026 Q3 | $2.02B | -2.9% | $1.58 | — | — |
| RDNTRadNet, Inc. | FY2026 Q3 | $638.26M | +22.1% | $0.05 | -28.6% | — |
| GRALGRAIL, Inc. | FY2026 Q3 | $37.54M | +3.7% | $-2.21 | — | — |
| BLLNBillionToOne, Inc. | FY2026 Q3 | $122.98M | +47.2% | $0.32 | +220.0% | — |
| ADPTAdaptive Biotechnologies Corp | FY2026 Q3 | $83.9M | -10.7% | $0.02 | -66.7% | — |
| SHCSotera Health Co | FY2026 Q3 | $324.89M | +4.4% | $0.20 | +17.6% | — |
| CDNACareDx, Inc. | FY2026 Q3 | $139.36M | +39.3% | $0.35 | — | — |
| VCYTVERACYTE, INC. | FY2026 Q3 | $151.75M | +15.1% | $0.38 | +58.3% | — |
| PSNLPersonalis, Inc. | FY2026 Q3 | $25.6M | +76.6% | $-0.32 | — | — |
| WGSGeneDx Holdings Corp. | FY2026 Q3 | $123.1M | +5.4% | $-0.41 | — | — |
| OPKOPKO HEALTH, INC. | FY2026 Q3 | $65.41M | -56.9% | $-0.07 | — | — |
| CSTLCASTLE BIOSCIENCES INC | FY2026 Q3 | $102.89M | +23.9% | $-0.13 | — | — |
| MYGNMYRIAD GENETICS INC | FY2026 Q3 | $202.7M | -1.5% | $-0.46 | — | — |
| XGNEXAGEN INC. | FY2026 Q3 | $18.42M | +6.8% | $-0.25 | — | — |
| BDSXBIODESIX INC | FY2026 Q3 | $24.04M | +10.4% | $-0.75 | — | — |
| 144510GC CELL CORPORATION | FY2026 Q2 | ₩41.6B | -3.1% | ₩157.00 | — | — |
| FONRFONAR CORP | FY2023 Q3 | $72.78M | — | $1.43 | — | — |
| IMDXInsight Molecular Diagnostics Inc. | FY2026 Q2 | $239K | -53.9% | $-0.31 | — | — |
| 153710Optipharm.CO.,LTD | FY2026 Q2 | ₩6.59B | +13.8% | ₩-15.00 | — | — |
YoY = vs. the same quarter last year · Surprise = EPS actual vs. consensus. Latest reported quarter per company, from disclosed earnings filings. QoQ is omitted because quarterly filings don’t break out Q4 (US) and report cumulatively (KR).